Xynos Konstantinos 4

4 · Replimune Group, Inc. · Filed Apr 7, 2026

AI-generated summary of this filing

Updated Apr 8, 2026

Replimune (REPL) CMO Konstantinos Xynos Receives Stock Awards

What Happened

Konstantinos Xynos, Chief Medical Officer of Replimune Group, was granted two awards on April 1, 2026: 50,000 restricted stock units (RSUs) and 75,000 derivative awards (stock option-style), each acquired at a $0.00 price. The combined awards represent 125,000 potential shares of Replimune common stock. These were grants/awards (compensation), not open-market purchases or sales.

Key Details

Transaction date: April 1, 2026; Form 4 filed April 7, 2026 (filing marked late due to an inadvertent administrative error).
Price: $0.00 for both awards (no cash paid by the insider).
Amounts: 50,000 RSUs (Footnote F1) and 75,000 derivative shares/options (Footnote F2) — total 125,000 shares potentially issuable.
Vesting (per filing footnotes):
- F1 (RSUs): 25% vest on May 15, 2027; remaining vest in three roughly equal annual installments through May 15, 2030, subject to continuous service.
- F2 (option-style): 25% of shares underlying the option vest on April 1, 2027; remaining shares vest in ~36 equal monthly installments thereafter.
Shares owned after the transaction: not specified in the provided filing details.
Timeliness: Filing late (reported reason: inadvertent administrative error). Late filings reduce immediate transparency but do not change the nature of the grants.

Context

These awards are compensation tied to future vesting and continued service; they do not represent an immediate cash purchase or sale and therefore are not a direct market-confidence signal. RSUs convert to actual shares only as they vest; the option-style award similarly vests over time before shares are issuable or exercisable.

Form 4

Period: 2026-04-01

Chief Medical Officer

Transactions

Award
Common Stock
[F1]
2026-04-01+50,000→ 249,685 total
Award
Employee Stock Option (right to buy)
[F2]
2026-04-01+75,000→ 75,000 total
Exercise: $7.61Exp: 2036-04-01→ Common Stock (75,000 underlying)

Footnotes (2)

[F1]Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2027 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2030, subject to the Reporting Person's continuous service to the Issuer.
[F2]25% of the shares underlying this stock option vest on April 1, 2027, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.

Signature

/s/ Shawn Glidden, attorney-in-fact|2026-04-07

1 file